Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04391842 · ClinicalTrials.gov registry record · Phase 1

Sustained Acoustic Medicine (SAM) Combined With a Diclofenac Ultrasound Coupling Patch for Knee Osteoarthritis

A Phase 1 study of Arthritis and Osteo Arthritis Knee, sponsored by ZetrOZ.

Completed
Registry status
Phase 1
Development phase
34
Enrollment target
1
Study location

NCT04391842 is a Phase 1 study of Arthritis and Osteo Arthritis Knee that has completed, run by ZetrOZ. The registered enrollment target is 34 participants, below the 4,509-participant average among 48 other Arthritis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04391842, a Phase 1 study of Arthritis and Osteo Arthritis Knee, has completed, sponsored by ZetrOZ.

COMPLETED
Registry status
Phase 1
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to measure the effectiveness of Sustained Acoustic Medicine (SAM) treatment combined with diclofenac ultrasound coupling gel in patients with stage II and stage III knee osteoarthritis. The ability of the device to reduce pain, increase mobility, increase function of the affected leg, and improve quality of life in patients with knee osteoarthritis will be evaluated.

Interventions

  • COMBINATION_PRODUCT Sustained Acoustic Device with 1% Diclofenac patch

Study Locations (1)

New York

  • Cayuga Medical Center - - Dryden

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2019-09-01
Est. Completion 2019-12-31
Phase Phase 1

Sponsor

ZetrOZ

17 total trials

What the Registry Record Tells You About NCT04391842

The ClinicalTrials.gov registry entry for NCT04391842 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,509-participant average among 48 other Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is ZetrOZ, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Sustained Acoustic Device with 1% Diclofenac patch is the first listed.

NCT04391842 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT04391842 about?

NCT04391842 is a clinical study titled "Sustained Acoustic Medicine (SAM) Combined With a Diclofenac Ultrasound Coupling Patch for Knee Osteoarthritis". The purpose of this study is to measure the effectiveness of Sustained Acoustic Medicine (SAM) treatment combined with diclofenac ultrasound coupling gel in patients with stage II and stage III knee osteoarthritis. The ability of the device to reduce pain, increase mobility, increase function of the...

What is the current status of trial NCT04391842?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2019-09-01. Estimated completion is 2019-12-31.

What conditions does trial NCT04391842 study?

This clinical trial studies the following conditions: Arthritis, Osteo Arthritis Knee.

What interventions are being tested in trial NCT04391842?

The interventions under investigation include: Sustained Acoustic Device with 1% Diclofenac patch (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT04391842?

This trial is sponsored by ZetrOZ, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04391842 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.